Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.

Zeng, Cong; Evans, John P; Reisinger, Sarah; Woyach, Jennifer; Liscynesky, Christina; Boghdadly, Zeinab El; Rubinstein, Mark P; Chakravarthy, Karthik; Saif, Linda; Oltz, Eugene M; Gumina, Richard J; Shields, Peter G; Li, Zihai; Liu, Shan-Lu

Zeng, Cong; Evans, John P; Reisinger, Sarah; Woyach, Jennifer; Liscynesky, Christina; Boghdadly, Zeinab El; Rubinstein, Mark P; Chakravarthy, Karthik; Saif, Linda; Oltz, Eugene M; Gumina, Richard J; Shields, Peter G; Li, Zihai; Liu, Shan-Lu.

Afiliación

Zeng C; Center for Retrovirus Research, The Ohio State University, Columbus, OH, 43210, USA.
Evans JP; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210, USA.
Reisinger S; Center for Retrovirus Research, The Ohio State University, Columbus, OH, 43210, USA.
Woyach J; Department of Veterinary Biosciences, The Ohio State University, Columbus, OH, 43210, USA.
Liscynesky C; Molecular, Cellular and Developmental Biology Program, The Ohio State University, 43210, Columbus, OH, USA.
Boghdadly ZE; Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University, Columbus, OH, 43210, USA.
Rubinstein MP; Division of Hematology, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
Chakravarthy K; Internal Medicine, Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Saif L; Internal Medicine, Division of Infectious Diseases, Department of Internal Medicine, The Ohio State University, Columbus, OH, 43210, USA.
Oltz EM; Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.
Gumina RJ; Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, 43210, USA.
Shields PG; Center for Food Animal Health, Animal Sciences Department, OARDC, College of Food, Agricultural and Environmental Sciences,, Wooster, OH, 44691, USA.
Li Z; Veterinary Preventive Medicine Department, College of Veterinary Medicine, The Ohio State University, 44691, Wooster, OH, USA.
Liu SL; Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State University, Columbus, OH, 43210, USA.

Cell Biosci ; 11(1): 197, 2021 Nov 21.

Article en En | MEDLINE | ID: mdl-34802457

ABSTRACT

ABSTRACT

There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for immunocompromised patients. In this study, we determined the neutralizing antibody response in 160 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin's lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer patients exhibited reduced neutralizing antibody titer (NT50) compared to HCWs; (2) CLL and NHL patients exhibited the lowest NT50 levels, with 50-60% of them below the detection limit; (3) mean NT50 levels in patients with CLL and NHL was ~2.6 fold lower than those with solid tumors; and (4) cancer patients who received anti-B cell therapy exhibited significantly reduced NT50 levels. Our results demonstrate an urgent need for novel immunization strategies for cancer patients against SARS-CoV-2, particularly those with hematological cancers and those on anti-B cell therapies.

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Cell Biosci Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos